Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 83 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: COVID-19 Vaccination
Interventions: Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB); Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York • The Bronx, New York

Conditions: Influenza
Interventions: Flucelvax(R), Human Challenge virus; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions: Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 79 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions: Aptitude Medical Systems Metrix COVID/Flu Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: 2 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts

Conditions: Influenza
Interventions: VAX161 [STF2.HA5 H5N1]; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza A Virus Infection
Interventions: High-titer anti-influenza plasma, Low-titer anti-influenza plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Weeks and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Influenza, Human, Influenza, Flu
Interventions: Diassess Influenza A and B Test; Device
Lead sponsor: Diassess Inc.; Industry
Eligibility: Not listed
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Healthy
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 19
States / cities: Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more

Conditions: Healthy
Interventions: VGX-3400X; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Conditions: Influenza A Subtype H5N1 Infection
Interventions: H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine; Biological
Lead sponsor: Access to Advanced Health Institute (AAHI); Other
Eligibility: 18 Years to 49 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Pregnancy
Interventions: Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: Avonex; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Monovalent influenza virus vaccine, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 3
States / cities: Daytona Beach, Florida • Portland, Oregon • Austin, Texas

Conditions: COVID-19, Coronavirus Disease 2019, Influenza
Interventions: COVID-19 Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone); Biological
Lead sponsor: ID Biomedical Corporation, Quebec; Industry
Eligibility: 50 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Influenza
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Influenza
Interventions: Inactivated H1N1 vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • Rochester, New York

Conditions: Vaccination, Influenza
Interventions: Local educational information, National educational information; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Months and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Influenza
Interventions: 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Community Care Intervention to Decrease COVID-19 Vaccination Inequities

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Clinical Performance of the Diassess Influenza A and B Test

Cigarette Smoke and Susceptibility to Influenza Infection

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

H5 Booster After a Two Dose Schedule

Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses